Sugi Predict

Sugi Predict / Compounds / SCHEMBL21807012

SCHEMBL21807012

SCHEMBL21807012

CCCCCCCCC(CC)OC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNc1c(N(C)C)c(=O)c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ LMNA P02545 4/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ PRKCA P17252 1/20 0.35
▸ PRKCE Q02156 1/20 0.35
▸ PRKCQ Q04759 1/20 0.35
▸ PRKCD Q05655 1/20 0.35
▸ CNR1 P21554 1/20 0.35
▸ CNR2 P34972 1/20 0.35
▸ DAGLA Q9Y4D2 1/20 0.35
▸ DNM1 Q05193 1/20 0.34
▸ TLR2 O60603 2/20 0.33
▸ TLR4 O00206 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ GMNN O75496 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ BLM P54132 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18641797 0.92 DNM1 (0.40) MAPTMAPK1LMNAALDH1A1PRKCA
SCHEMBL21842689 0.89 MAPK1 (0.39) MAPTMAPK1EPHX2LMNAALDH1A1
SCHEMBL21230897 0.89 MAPK1 (0.39) MAPTMAPK1EPHX2LMNAALDH1A1
SCHEMBL21807037 0.89 MAPK1 (0.39) MAPTMAPK1EPHX2LMNAALDH1A1
SCHEMBL21807177 0.89 MAPK1 (0.39) MAPTMAPK1EPHX2LMNAALDH1A1
SCHEMBL20500755 0.89 MAPK1 (0.39) MAPTMAPK1EPHX2LMNAALDH1A1
SCHEMBL21842688 0.89 MAPK1 (0.39) MAPTMAPK1EPHX2LMNAALDH1A1
SCHEMBL29315165 0.89 MAPK1 (0.39) MAPTMAPK1EPHX2LMNAALDH1A1
SCHEMBL21807015 0.88 GRIN2D (0.42) MAPTMAPK1EPHX2LMNAALDH1A1
SCHEMBL22646042 0.88 EPHX2 (0.40) MAPTMAPK1EPHX2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024026482-A1 LIPID NANOPARTICLE COMPOSITIONS COMPRISING SURFACE LIPID DERIVATIVES AND RELATED USES MODERNATX, INC. (US) 2024-02-01 — — WO disclosed
US-20220409536-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2022-12-29 — — US disclosed
EP-3853202-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ModernaTX, Inc. (US) 2021-07-28 — — EP disclosed
WO-2020061367-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS MODERNATX, INC. (US) 2020-03-26 — — WO disclosed
WO-2020061367-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS MODERNATX, INC. (US) 2020-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220409536-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS LNPK, PLTP, PLIN3 MAPT 2478/4885MAPK1 3062/4885EPHX2 3348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.